Polyendocrine metabolic syndrome doesn't end at menopause and neither should its care, research shows

Polycystic Ovary Syndrome, which has just been renamed Polyendocrine Ovarian Syndrome (PMOS), is the most common hormonal and metabolic disorder affecting women of reproductive age, impacting up to 13% of this population and contributing to nearly 40% of infertility cases worldwide. The condition is marked by a complex combination of hormonal imbalance, insulin resistance, metabolic dysfunction and inflammation, often leading to irregular menstrual cycles, weight gain and increased cardiovascular and diabetes risk.